Sign inJoin waitlistJoin the waitlist

DB

David Berz

Physician · Valkyrie Pharmaceutics

Credentials: · · · · ·

History

Valkyrie Pharmaceutics
2026–Present

Hematology and Medical Oncology
2002–2005
Internal Medicine
1999–2002
Doctor of Medicine
1995–1999

Research

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
Journal of Thoracic Oncology · 2016 · 253 citations
Cryopreservation of hematopoietic stem cells
Review · American Journal of Hematology · 2007 · First of 5 authors · Corresponding · 177 citations
Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription
Experimental Hematology · 2010 · 162 citations

GC
Gerald Colvin
10 papers
Peter Quesenberry
6 papers
AS
Alexander Spira
4 papers
Ariel Birnbaum
4 papers
Eric Winer
4 papers
Howard Safran
4 papers
RJ
Robert Jotte
4 papers
SA
Sanjay Awasthi
4 papers
Elise McCormack-Granja
3 papers · 3 as a resident
HW
Harold Wanebo
3 papers
Ross Camidge
3 papers
Sherry Weitzen
3 papers · 1 as a resident

Clinical trials

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Site PI · Recruiting · Phase 3
SystImmune Inc.
2026–2031
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028